Adverse effects associated with the intrathecal administration of ziconotide

Richard D. Penn*, Judith A. Paice

*Corresponding author for this work

Research output: Contribution to journalArticle

151 Scopus citations

Abstract

The ω-conopeptide, ziconotide, is an N-type calcium-channel blocker that has been shown to produce antinociception in animals using formalin and hot-plate tests. Initial reports of intrathecal administration of ziconotide in cancer and AIDS patients whose pain was unrelieved with opioids demonstrated analgesic efficacy. Although adverse effects were reported, these appeared to be easily managed through dose reduction or symptomatic treatment. This clinical report describes the experiences of three patients with serious adverse effects associated with intrathecal ziconotide. (C) 2000 International Association for the Study of Pain.

Original languageEnglish (US)
Pages (from-to)291-296
Number of pages6
JournalPain
Volume85
Issue number1-2
DOIs
StatePublished - Mar 1 2000

Keywords

  • Conopeptide
  • Intrathecal
  • N-type calcium-channel blocker
  • Neuropathic pain
  • Side effects
  • Ziconotide

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Anesthesiology and Pain Medicine

Fingerprint Dive into the research topics of 'Adverse effects associated with the intrathecal administration of ziconotide'. Together they form a unique fingerprint.

  • Cite this